The data safety monitoring board (DSMB) meeting reviewed 28-week data for approximately 50% of the patients in the study. The DSMB noted in their report very few dropouts and that the study appears to be proceeding well. In addition, the report indicated that baseline MRI data is consistent with the assumptions used in the design of the study.
David McWilliams, president and CEO of Opexa said: ” We have delivered all Tovaxin doses to patients in the study and now look forward to presenting 52-week topline results of the TERMS Phase IIb study in September.”